<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Trastuzumab</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Trastuzumab">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Trastuzumab</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Trastuzumab</b>, sold under the brand name <b>Herceptin</b> among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.<span class="mw-ref" id="cite_ref-AHFS2016_3-0"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Herceptin_FDA_label_4-0"><a href="#cite_note-Herceptin_FDA_label-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Herceptin_EPAR_6-0"><a href="#cite_note-Herceptin_EPAR-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> It is specifically used for cancer that is HER2 receptor positive.<span class="mw-ref" id="cite_ref-AHFS2016_3-1"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It may be used by itself or together with other chemotherapy medication.<span class="mw-ref" id="cite_ref-AHFS2016_3-2"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Trastuzumab is given by slow injection into a vein and injection just under the skin.<span class="mw-ref" id="cite_ref-AHFS2016_3-3"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-BNF69_7-0"><a href="#cite_note-BNF69-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>



<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Trastuzumab</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Trastuzumab_Fab-HER2_complex_1N8Z.png" tppabs="https://ptable.com/wiki/compounds/I/m/Trastuzumab_Fab-HER2_complex_1N8Z.png" data-file-width="1920" data-file-height="1824" data-file-type="bitmap" height="209" width="220"></figure-inline><div>Trastuzumab Fab region (cyan) binding HER2/neu (gold)</div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Monoclonal antibody</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Type</th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Source</th><td>Humanized (from mouse)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Target</th><td>HER2/neu</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Herceptin, Herzuma, Ogivri, others<span class="mw-ref" id="cite_ref-generic_1-0"><a href="#cite_note-generic-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/trastuzumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/trastuzumab.html'" tppabs="https://www.drugs.com/monograph/trastuzumab.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Trastuzumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Trastuzumab'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Trastuzumab" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Trastuzumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Trastuzumab'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Trastuzumab" class="external text external">Trastuzumab</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Trastuzumab&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Trastuzumab&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Trastuzumab&SearchType=BasicSearch" class="external text external">Trastuzumab</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>D<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_Pregnancy_2-0"><a href="#cite_note-Drugs.com_Pregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_Pregnancy_2-1"><a href="#cite_note-Drugs.com_Pregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Intravenous, subcutaneous</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Antineoplastic agent</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L01XC03<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L01XC03  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L01XC03'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L01XC03" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li><small><abbr class="country-name">EU</abbr>:</small><span> </span>Rx-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Unknown, possibly reticuloendothelial system.</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>2-12 days</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=180288-69-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=180288-69-1'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=180288-69-1" class="external text external">180288-69-1</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem<span> </span><span style="font-weight:normal"><abbr>SID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507516  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507516'" tppabs="https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507516" class="external text external">46507516</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00072  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00072'" tppabs="https://www.drugbank.ca/drugs/DB00072" class="external text external">DB00072</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=P188ANX8CK  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=P188ANX8CK'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=P188ANX8CK" class="external text external">P188ANX8CK</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D03257  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D03257'" tppabs="https://www.kegg.jp/entry/D03257" class="external text external">D03257</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201585  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201585'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201585" class="external text external">ChEMBL1201585</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.224.377  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.224.377'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.224.377" class="external text external">100.224.377</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>6470</sub><span>H</span><sub>10012</sub><span>N</span><sub>1726</sub><span>O</span><sub>2013</sub><span>S</span><sub>42</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">145<span style="margin-left:.25em;">531</span>.86</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470612477&page2=Trastuzumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470612477&page2=Trastuzumab'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=470612477&page2=Trastuzumab" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


<p>Common side effects include fever, infection, cough, headache, trouble sleeping, and rash.<span class="mw-ref" id="cite_ref-AHFS2016_3-4"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Other severe side effects include heart failure, allergic reactions, and lung disease.<span class="mw-ref" id="cite_ref-AHFS2016_3-5"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Use during pregnancy may harm the baby.<span class="mw-ref" id="cite_ref-Drugs.com_Pregnancy_2-2"><a href="#cite_note-Drugs.com_Pregnancy-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication.<span class="mw-ref" id="cite_ref-AHFS2016_3-6"><a href="#cite_note-AHFS2016-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


<p>Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-Herceptin_EPAR_6-1"><a href="#cite_note-Herceptin_EPAR-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_9-0"><a href="#cite_note-WHO21st-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> A biosimilar was approved in the European Union in November 2017, and in the United States in December 2018.<span class="mw-ref" id="cite_ref-Ontruzant_EPAR_10-0"><a href="#cite_note-Ontruzant_EPAR-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-FDA_Herzuma_PR_11-0"><a href="#cite_note-FDA_Herzuma_PR-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-Herzuma_FDA_approval_12-0"><a href="#cite_note-Herzuma_FDA_approval-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>The safety and efficacy of trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or <a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">lapatinib</a>) for the treatment of metastatic breast cancer. The overall hazard ratios for overall survival and progression free survival were 0.82 and 0.61, respectively. It was difficult to accurately ascertain the true impact of trastuzumab on survival, as in three of the seven trials, over half of the patients in the control arm were allowed to cross-over and receive trastuzumab after their cancer began to progress.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span>  Thus, this analysis likely underestimates the true survival benefit associated with trastuzumab treatment in this population.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> In these trials, trastuzumab also increased the risk of heart problems, including heart failure and left ventricular ejection fraction decline.</p>

<p>In early-stage HER2-positive breast cancer, trastuzumab-containing regimens improved overall survival (HR = 0.66) and disease-free survival (HR = 0.60). Increased risk of heart failure (RR = 5.11) and decline in left ventricular ejection fraction (RR = 1.83) were seen in these trials as well. Two trials involving shorter term treatment with trastuzumab did not differ in efficacy from longer trials, but produced less cardiac toxicity.<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>

<p>The original studies of trastuzumab showed that it improved overall survival in late-stage (metastatic) HER2-positive breast cancer from 20.3 to 25.1 months.<span class="mw-ref" id="cite_ref-Hudis_2007_16-0"><a href="#cite_note-Hudis_2007-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> In early-stage HER2-positive breast cancer, it reduces the risk of cancer returning after surgery. The absolute reduction in the risk of cancer returning within 3 years was 9.5%, and the absolute reduction in the risk of death within 3 years was reduced by 3%. However, it increases serious heart problems by an absolute risk of 2.1%, though the problems may resolve if treatment is stopped.<span class="mw-ref" id="cite_ref-Cochrane2012_17-0"><a href="#cite_note-Cochrane2012-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>Trastuzumab has had a "major impact in the treatment of HER2-positive metastatic breast cancer."<span class="mw-ref" id="cite_ref-TanSwain_18-0"><a href="#cite_note-TanSwain-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone.<span class="mw-ref" id="cite_ref-NahtaEsteva_19-0"><a href="#cite_note-NahtaEsteva-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>

<p>It is possible to determine the "erbB2 status" of a tumor, which can be used to predict efficacy of treatment with trastuzumab. If it is determined that a tumor is overexpressing the erbB2 oncogene and the patient has no significant pre-existing heart disease, then a patient is eligible for treatment with trastuzumab.<span class="mw-ref" id="cite_ref-YuHung_20-0"><a href="#cite_note-YuHung-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> It is surprising that although trastuzumab has great affinity for HER2 and high doses can be administered (because of its low toxicity), 70% of HER2+ patients do not respond to treatment. In fact resistance to the treatment develops rapidly, in virtually all patients. A mechanism of resistance involves failure to downregulate p27 (Kip1)  <span class="mw-ref" id="cite_ref-Le_2005_21-0"><a href="#cite_note-Le_2005-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> as well as suppressing p27 translocation to the nucleus in breast cancer, enabling cdk2 to induce cell proliferation.<span class="mw-ref" id="cite_ref-Kute_22-0"><a href="#cite_note-Kute-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Duration_of_treatment">Duration of treatment</h3></summary>
    
<p>The optimal duration of add-on trastuzumab treatment after surgery for early breast cancer is currently unknown. One year of treatment is generally accepted based on current clinical trial evidence that demonstrated the superiority of one-year treatment over none.<span class="mw-ref" id="cite_ref-Romond_23-0"><a href="#cite_note-Romond-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-Piccart_24-0"><a href="#cite_note-Piccart-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> However, a small Finnish trial also showed similar improvement with nine weeks of treatment over no therapy.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> Because of the lack of direct head-to-head comparison in clinical trials, it is unknown whether a shorter duration of treatment may be just as effective (with fewer side effects) than the currently accepted practice of treatment for one year.  Debate about treatment duration has become a relevant issue for many public health policy makers because administering trastuzumab for a year is very expensive.  Consequently, some countries with a taxpayer-funded public health system, such as New Zealand, chose to fund limited adjuvant therapy.<span class="mw-ref" id="cite_ref-Metcalfe_26-0"><a href="#cite_note-Metcalfe-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span>  However, subsequently New Zealand has revised its policy and now funds trastuzumab treatment for up to 12 months.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    

<p>Some of the common side effects of trastuzumab are flu-like symptoms (such as fever, chills and mild pain), nausea and diarrhea.<span class="mw-ref" id="cite_ref-Breast_Cancer_Care_28-0"><a href="#cite_note-Breast_Cancer_Care-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Cardiac_toxicity">Cardiac toxicity</h3></summary>
    
<p>One of the more serious complications of trastuzumab is its effect on the heart, although this is rare.<span class="mw-ref" id="cite_ref-Breast_Cancer_Care_28-1"><a href="#cite_note-Breast_Cancer_Care-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span> In 2-7% of cases,<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> trastuzumab is associated with cardiac dysfunction, which includes congestive heart failure. As a result, regular cardiac screening with either a MUGA scan or echocardiography is commonly undertaken during the trastuzumab treatment period. The decline in ejection fraction appears to be reversible.<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span></p>

<p>Trastuzumab downregulates neuregulin-1 (NRG-1), which is essential for the activation of cell survival pathways in cardiomyocytes and the maintenance of cardiac function. NRG-1 activates the MAPK pathway and the PI3K/AKT pathway as well as focal adhesion kinases (FAK). These are all significant for the function and structure of cardiomyocytes. Trastuzumab can therefore lead to cardiac dysfunction.<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>

<p>Approximately 10% of people are unable to tolerate the drug because of pre-existing heart problems; physicians are balancing the risk of recurrent cancer against the higher risk of death due to cardiac disease in this population.  The risk of cardiomyopathy is increased when trastuzumab is combined with anthracycline chemotherapy (which itself is associated with cardiac toxicity).</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Birth_control">Birth control</h3></summary>
    
<p>Women having periods (or whose periods stopped due to chemotherapy) may need to use barrier contraception (such as condoms) while taking trastuzumab, and for at least six months afterwards. This is because of the possibility of harming a developing fetus.<span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p></p>

<p>The <i>HER2</i> gene (also known as <i>HER2/neu</i> and <i>ErbB2</i> gene) is amplified in 20–30% of early-stage breast cancers.<span class="mw-ref" id="cite_ref-Le_2005_21-1"><a href="#cite_note-Le_2005-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> Trastuzumab is a monoclonal antibody targeting HER2, inducing an immune-mediated response that causes internalization and downregulation of HER2. It may also upregulate cell cycle inhibitors such as p21<sup>Waf1</sup> and p27<sup>Kip1</sup>.<span class="mw-ref" id="cite_ref-Bange_33-0"><a href="#cite_note-Bange-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>

<p>The HER2 pathway promotes cell growth and division when it is functioning normally; however, when it is overexpressed, cell growth accelerates beyond its normal limits. In some types of cancer, the pathway is exploited to promote rapid cell growth and proliferation and hence tumor formation.<span class="mw-ref" id="cite_ref-cancer_34-0"><a href="#cite_note-cancer-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span>  The EGF pathway includes the receptors HER1 (EGFR), HER2, HER3, and HER4; the binding of ligands (e.g. EGF etc.) to HER receptors is required to activate the pathway.<span class="mw-ref" id="cite_ref-cancer_34-1"><a href="#cite_note-cancer-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span>  The pathway initiates the MAP kinase pathway as well as the PI3 kinase/AKT pathway, which in turn activates the NF-κB pathway.<span class="mw-ref" id="cite_ref-Feldman_35-0"><a href="#cite_note-Feldman-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span>  In cancer cells the HER2 protein can be expressed up to 100 times more than in normal cells (2 million versus 20,000 per cell).<span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span>  This overexpression leads to strong and constant proliferative signaling and hence tumor formation. Overexpression of HER2 also causes deactivation of checkpoints, allowing for even greater increases in proliferation.</p>

<p>The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell (molecules called EGFs) to inside the cell, and turn genes on and off. The HER (human epidermal growth factor receptor) protein, binds to human epidermal growth factor, and stimulates cell proliferation. In some cancers, notably certain types of breast cancer, HER2 is over-expressed and causes cancer cells to reproduce uncontrollably.<span class="mw-ref" id="cite_ref-Hudis_2007_16-1"><a href="#cite_note-Hudis_2007-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>

<p>HER2 extends across the cell membrane, and carries signals from outside the cell to the inside. Signaling compounds called mitogens (specifically EGF in this case) arrive at the cell membrane, and bind to the extracellular domain of the HER family of receptors. Those bound proteins then link (dimerize), activating the receptor. HER2 sends a signal from its intracellular domain, activating several different biochemical pathways. These include the PI3K/Akt pathway and the MAPK pathway. Signals on these pathways promote cell proliferation and the growth of blood vessels to nourish the tumor (angiogenesis).<span class="mw-ref" id="cite_ref-Menard_37-0"><a href="#cite_note-Menard-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>

<p>Normal cell division—mitosis—has checkpoints that keep cell division under control. Some of the proteins that control this cycle are called cdk2 (CDKs). Overexpression of HER2 sidesteps these checkpoints, causing cells to proliferate in an uncontrolled fashion.<span class="mw-ref" id="cite_ref-Kute_22-1"><a href="#cite_note-Kute-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> This is caused by phosphorylation by Akt.</p>

<p>Trastuzumab binds to domain IV of the<span class="mw-ref" id="cite_ref-38"><a href="#cite_note-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span> extracellular segment of the HER2/neu receptor. Monoclonal antibodies that bind to this region have been shown to reverse the phenotype of HER2/neu expressing tumor cells.<span class="mw-ref" id="cite_ref-39"><a href="#cite_note-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> Cells treated with trastuzumab undergo arrest during the G1 phase of the cell cycle so there is reduced proliferation. It has been suggested that trastuzumab does not alter HER-2 expression, but downregulates activation of AKT.<span class="mw-ref" id="cite_ref-Kute_22-2"><a href="#cite_note-Kute-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> In addition, trastuzumab suppresses angiogenesis both by induction of antiangiogenic factors and repression of proangiogenic factors. It is thought that a contribution to the unregulated growth observed in cancer could be due to proteolytic cleavage of HER2/neu that results in the release of the extracellular domain. One of the most relevant proteins that trastuzumab activates is the tumor suppressor p27 (kip1), also known as CDKN1B.<span class="mw-ref" id="cite_ref-Le_2005_21-2"><a href="#cite_note-Le_2005-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> Trastuzumab has been shown to inhibit HER2/neu ectodomain cleavage in breast cancer cells.<span class="mw-ref" id="cite_ref-Albenall_40-0"><a href="#cite_note-Albenall-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></p>

<p>Experiments in laboratory animals indicate that antibodies, including trastuzumab, when bound to a cell, induce immune cells to kill that cell, and that such antibody-dependent cell-mediated cytotoxicity is another important mechanism of action.<span class="mw-ref" id="cite_ref-41"><a href="#cite_note-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span></p>

<p>There may be other undiscovered mechanisms by which trastuzumab induces regression in cancer.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Predicting_response">Predicting response</h2></summary>
    
<p>Trastuzumab inhibits the effects of overexpression of HER2. If the breast cancer does not overexpress HER2, trastuzumab will have no beneficial effect (and may cause harm).  Doctors use laboratory tests to discover whether HER2 is overexpressed. In the routine clinical laboratory, the most commonly employed methods for this are immunohistochemistry (IHC) and either silver, chromogenic or fluorescent in situ hybridisation (SISH/CISH/FISH). HER2 amplification can be detected by virtual karyotyping of formalin-fixed paraffin embedded tumor. Virtual karyotyping has the added advantage of assessing copy number changes throughout the genome, in addition to detecting HER-2 amplification (but not overexpression). Numerous PCR-based methodologies have also been described in the literature.<span class="mw-ref" id="cite_ref-Jennings_42-0"><a href="#cite_note-Jennings-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> It is also possible to estimate <i>HER2</i> copy number from microarray data.<span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></p>

<p>There are two FDA-approved commercial kits available for HER2 IHC; Dako HercepTest<span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> and Ventana Pathway.<span class="mw-ref" id="cite_ref-ventanamed1_45-0"><a href="#cite_note-ventanamed1-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span> These are highly standardised, semi-quantitative assays which stratify expression levels into; 0 (&lt;20,000 receptors per cell, no visible expression), 1+ (~100,000 receptors per cell, partial membrane staining, &lt; 10% of cells overexpressing HER-2), 2+ (~500,000 receptors per cell, light to moderate complete membrane staining, &gt; 10% of cells overexpressing HER-2), and 3+ (~2,000,000 receptors per cell, strong complete membrane staining, &gt; 10% of cells overexpressing HER-2). The presence of cytoplasmic expression is disregarded. Treatment with trastuzumab is indicated in cases where HER2 expression has a score of 3+. However, IHC has been shown to have numerous limitations, both technical and interpretative, which have been found to impact on the reproducibility and accuracy of results, especially when compared with ISH methodologies. It is also true, however, that some reports have stated that IHC provides excellent correlation between gene copy number and protein expression.</p>

<p>Fluorescent in situ hybridization (FISH) is viewed as being the "gold standard" technique in identifying patients who would benefit from trastuzumab, but it is expensive and requires fluorescence microscopy and an image capture system. The main expense involved with CISH is in the purchase of FDA-approved kits, and as it is not a fluorescent technique it does not require specialist microscopy and slides may be kept permanently. Comparative studies of CISH and FISH have shown that these two techniques show excellent correlation. The lack of a separate chromosome 17 probe on the same section is an issue with regards to acceptance of CISH.  As of June 2011 Roche has obtained FDA approval for the INFORM HER2 Dual ISH DNA Probe cocktail <span class="mw-ref" id="cite_ref-46"><a href="#cite_note-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span> developed by Ventana Medical Systems.<span class="mw-ref" id="cite_ref-ventanamed1_45-1"><a href="#cite_note-ventanamed1-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span>  The DDISH (Dual-chromagen/Dual-hapten In-situ hybridization) cocktail uses both HER2 and Chromosome 17 hybridization probes for chromagenic visualization on the same tissue section.  The detection can be achieved by using a combination of ultraView SISH(silver in-situ hybridization) and ultraView Red ISH for deposition of distinct chromgenic precipitates at the site of DNP or DIG labeled probes.<span class="mw-ref" id="cite_ref-47"><a href="#cite_note-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span></p>

<p>Currently the recommended assays are a combination of IHC and FISH, whereby IHC scores of 0 and 1+ are negative (no trastuzumab treatment), scores of 3+ are positive (trastuzumab treatment), and score of 2+ (equivocal case) is referred to FISH for a definitive treatment decision. Industry best practices indicate the use of FDA-cleared Automated Tissue Image Systems by laboratories for automated processing of specimens, thereby reducing process variability, avoiding equivocal cases, and ensuring maximum efficacy of trastuzumab therapy.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Resistance">Resistance</h2></summary>
    
<p>One of the challenges in the treatment of breast cancer patients  by herceptin is our understanding towards herceptin resistance.  In the last decade, several assays have been performed to understand the mechanism of Herceptin resistance with/without supplementary drugs. Recently, all this information has been collected and compiled in form of a database HerceptinR.<span class="mw-ref" id="cite_ref-48"><a href="#cite_note-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span> This database <a href="javascript:if(confirm('http://crdd.osdd.net/raghava/herceptinr/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://crdd.osdd.net/raghava/herceptinr/'" tppabs="http://crdd.osdd.net/raghava/herceptinr/" class="external text external">HerceptinR</a> is a collection of assays performed to test sensitivity or resistance of Herceptin Antibodies towards breast cancer cell lines. This database provides comprehensive information about experimental data perform to understanding factors behind herceptin resistance as well as assays performed for improving Herceptin sensitivity with the help of supplementary drugs. This is the first database developed to understand herceptin resistance that can be used for designing herceptin sensitive biomarkers.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>The drug was first discovered by scientists including Dr. Axel Ullrich and Dr. H. Michael Shepard at Genentech, Inc. in South San Francisco, CA.<span class="mw-ref" id="cite_ref-49"><a href="#cite_note-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span> Earlier discovery about the <i>neu</i> oncogene by Robert Weinberg's lab <span class="mw-ref" id="cite_ref-50"><a href="#cite_note-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span> and the monoclonal antibody recognizing the oncogenic receptor by Mark Greene's lab <span class="mw-ref" id="cite_ref-51"><a href="#cite_note-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> also contributed to the establishment of HER2 targeted therapies. Dr. Dennis Slamon subsequently worked on trastuzumab's development. A book about Dr. Slamon's work was made into a television film called <i>Living Proof</i>, that premiered in 2008. Genentech developed trastuzumab jointly with UCLA, beginning the first clinical trial with 15 women in 1992.<span class="mw-ref" id="cite_ref-52"><a href="#cite_note-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> By 1996, clinical trials had expanded to over 900 women, but due to pressure from advocates based on early success, Genentech worked with the FDA to begin a lottery system allowing 100 women each quarter access to the medication outside the trials.<span class="mw-ref" id="cite_ref-53"><a href="#cite_note-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> Herceptin was Fast-tracked by the FDA and gained approval in September 1998.</p>

<p>Biocon Ltd and its partner Mylan obtained regulatory approval to sell a biosimilar in 2014, but Roche contested the legality of the approval; that litigation ended in 2016, and Biocon and Mylan each introduced their own branded biosimilars.<span class="mw-ref" id="cite_ref-54"><a href="#cite_note-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Costs">Costs</h3></summary>
    
<p>Trastuzumab costs about <span style="white-space: nowrap">US$70,000</span> for a full course of treatment,<span class="mw-ref" id="cite_ref-55"><a href="#cite_note-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> Trastuzumab brought in $327 million in revenue for Genentech in the fourth quarter of 2007.</p>

<p>Australia has negotiated a lower price of A$50,000 per course of treatment.<span class="mw-ref" id="cite_ref-56"><a href="#cite_note-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span></p>

<p>Since October 2006, trastuzumab has been made available for Australian women and men with early-stage breast cancer via the Pharmaceutical Benefits Scheme.  This is estimated to cost the country over A$470 million for 4–5 years supply of the drug.<span class="mw-ref" id="cite_ref-57"><a href="#cite_note-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span></p>

<p>Roche has agreed with Emcure in India to make an affordable version of this cancer drug available to the Indian market.<span class="mw-ref" id="cite_ref-58"><a href="#cite_note-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span></p>

<p>Roche has changed the trade name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named Herclon would cost approximately RS75,000 INR (<span style="white-space: nowrap">US$</span>1,200)  in the Indian market.</p>

<p>On September 16, 2014, Genentech notified hospitals in the United States that, as of October, trastuzumab could only be purchased through their selected specialty drugs distributors not through the usual general line wholesalers. By being forced to purchase through specialty pharmacies, hospitals lost rebates from the big wholesalers and the ability to negotiate cost-minus discounts with their wholesalers.<span class="mw-ref" id="cite_ref-Time_2014_59-0"><a href="#cite_note-Time_2014-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Biosimilars">Biosimilars</h3></summary>
    


<p>By 2014, around 20 companies, particularly from emerging markets, were developing biosimilar versions of trastuzumab
after Roche/Genentech's patents expired in 2014 in Europe, and in 2019 in the United States.<span class="mw-ref" id="cite_ref-60"><a href="#cite_note-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span> In 2013, Roche/Genentech relinquished its patent right for the drug in India because of the difficult IP environment there.</p>

<p>In January 2015, BIOCAD announced the first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation. Iran also approved its own version of the monoclonal antibody in January 2016, as AryoTrust, and announced its readiness to export the drug to other countries in the Middle-East and Central Asia when trade sanctions were lifted.<span class="mw-ref" id="cite_ref-generic_1-1"><a href="#cite_note-generic-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-61"><a href="#cite_note-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span></p>

<p>In 2016, the investigational biosimilar <span class="new">MYL-1401O</span> has shown comparable efficacy and safety to the Herceptin branded trastuzumab.<span class="mw-ref" id="cite_ref-62"><a href="#cite_note-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span></p>  

<p>Trastuzumab-dkst (Ogivri, Mylan GmbH) was approved in the United States in December 2017, to "treat patients with breast cancer or gastric or gastroesophageal junction adenocarcinoma whose tumors overexpress the HER-2 gene."<span class="mw-ref" id="cite_ref-63"><a href="#cite_note-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span><span class="mw-ref" id="cite_ref-64"><a href="#cite_note-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span> Ogivri was approved for medical use in the European Union in December 2018.<span class="mw-ref" id="cite_ref-65"><a href="#cite_note-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span></p>

<p>In November 2017, the European Commission approved Ontruzant, a biosimilar-trastuzumab from Samsung Bioepis Co., Ltd, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.<span class="mw-ref" id="cite_ref-Ontruzant_EPAR_10-1"><a href="#cite_note-Ontruzant_EPAR-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> Ontruzant is the first trastuzumab biosimilar to receive regulatory approval in Europe.<span class="mw-ref" id="cite_ref-66"><a href="#cite_note-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span></p>

<p>Herzuma was approved for medical use in the European Union in February 2018.<span class="mw-ref" id="cite_ref-67"><a href="#cite_note-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span> Herzuma, a trastuzumab biosimilar, was approved in the United States in December 2018.<span class="mw-ref" id="cite_ref-Herzuma_FDA_approval_12-1"><a href="#cite_note-Herzuma_FDA_approval-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-FDA-Herzuma_68-0"><a href="#cite_note-FDA-Herzuma-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span><span class="mw-ref" id="cite_ref-FDA_Herzuma_PR_11-1"><a href="#cite_note-FDA_Herzuma_PR-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> The approval was based on comparisons of extensive structural and functional product characterization, animal data, human pharmacokinetic, clinical immunogenicity, and other clinical data demonstrating that Herzuma is biosimilar to US Herceptin.<span class="mw-ref" id="cite_ref-FDA_Herzuma_PR_11-2"><a href="#cite_note-FDA_Herzuma_PR-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Herzuma has been approved as a biosimilar, not as an interchangeable product.<span class="mw-ref" id="cite_ref-FDA_Herzuma_PR_11-3"><a href="#cite_note-FDA_Herzuma_PR-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>

<p>Kanjinti was approved for medical use in the European Union in May 2018.<span class="mw-ref" id="cite_ref-69"><a href="#cite_note-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span></p>

<p>Trazimera was approved for medical use in the European Union in July 2018.<span class="mw-ref" id="cite_ref-70"><a href="#cite_note-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span></p>

<p>Zercepac was approved for medical use in the European Union in July 2020.<span class="mw-ref" id="cite_ref-71"><a href="#cite_note-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Related_conjugates">Related conjugates</h3></summary>
    
<p>Apart from the biosimilars noted above, trastuzumab is also a component of some antibody-drug conjugates, such as trastuzumab emtansine. Another ADC, trastuzumab deruxtecan was approved for use in the United States in December 2019.<span class="mw-ref" id="cite_ref-72"><a href="#cite_note-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-generic-1"> <span id="mw-reference-text-cite_note-generic-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/international/trastuzumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/trastuzumab.html'" tppabs="https://www.drugs.com/international/trastuzumab.html" class="external text external">"Trastuzumab - Drugs.com"</a>. <i>www.drugs.com</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20170407085909/https://www.drugs.com/international/trastuzumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170407085909/https://www.drugs.com/international/trastuzumab.html'" tppabs="https://web.archive.org/web/20170407085909/https://www.drugs.com/international/trastuzumab.html" class="external text external">Archived</a> from the original on 7 April 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">21 December</span> 2016</span>.</cite></span></li><li id="cite_note-Drugs.com_Pregnancy-2"> <span id="mw-reference-text-cite_note-Drugs.com_Pregnancy-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/trastuzumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/trastuzumab.html'" tppabs="https://www.drugs.com/pregnancy/trastuzumab.html" class="external text external">"Trastuzumab Pregnancy and Breastfeeding Warnings"</a>. <i>Drugs.com</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20191203180757/https://www.drugs.com/pregnancy/trastuzumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191203180757/https://www.drugs.com/pregnancy/trastuzumab.html'" tppabs="https://web.archive.org/web/20191203180757/https://www.drugs.com/pregnancy/trastuzumab.html" class="external text external">Archived</a> from the original on 3 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">3 December</span> 2019</span>.</cite></span></li><li id="cite_note-AHFS2016-3"> <span id="mw-reference-text-cite_note-AHFS2016-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/trastuzumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/trastuzumab.html'" tppabs="https://www.drugs.com/monograph/trastuzumab.html" class="external text external">"Trastuzumab"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20161221162802/https://www.drugs.com/monograph/trastuzumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161221162802/https://www.drugs.com/monograph/trastuzumab.html'" tppabs="https://web.archive.org/web/20161221162802/https://www.drugs.com/monograph/trastuzumab.html" class="external text external">Archived</a> from the original on 21 December 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">8 December</span> 2016</span>.</cite></span></li><li id="cite_note-Herceptin_FDA_label-4"> <span id="mw-reference-text-cite_note-Herceptin_FDA_label-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2" class="external text external">"Herceptin- trastuzumab kit Herceptin- trastuzumab injection, powder, lyophilized, for solution"</a>. <i>DailyMed</i>. 30 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">28 July</span> 2020</span>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-certain-breast-and-stomach-cancers  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-certain-breast-and-stomach-cancers'" tppabs="https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-certain-breast-and-stomach-cancers" class="external text external">"FDA approves first biosimilar for the treatment of certain breast and stomach cancers"</a>. <i>U.S. Food and Drug Administration (FDA)</i> (Press release). 10 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-Herceptin_EPAR-6"> <span id="mw-reference-text-cite_note-Herceptin_EPAR-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/herceptin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/herceptin'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/herceptin" class="external text external">"Herceptin EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 July</span> 2020</span>.</cite></span></li><li id="cite_note-BNF69-7"> <span id="mw-reference-text-cite_note-BNF69-7" class="mw-reference-text"><cite class="citation book cs1"><i>British national formulary<span>&nbsp;</span>: BNF 69</i> (69 ed.). British Medical Association. 2015. p.<span>&nbsp;</span>626. ISBN<span>&nbsp;</span><bdi>9780857111562</bdi>.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20170128163102/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080591.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170128163102/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080591.htm'" tppabs="https://web.archive.org/web/20170128163102/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080591.htm" class="external text external">"Trastuzumab Product Approval Information - Licensing Action 9/25/98"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 18 December 2015. Archived from <a href="javascript:if(confirm('https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080591.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080591.htm'" tppabs="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080591.htm" class="external text external">the original</a> on 28 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">3 December</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-WHO21st-9"> <span id="mw-reference-text-cite_note-WHO21st-9" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-Ontruzant_EPAR-10"> <span id="mw-reference-text-cite_note-Ontruzant_EPAR-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/ontruzant  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/ontruzant'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/ontruzant" class="external text external">"Ontruzant EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 July</span> 2020</span>.</cite></span></li><li id="cite_note-FDA_Herzuma_PR-11"> <span id="mw-reference-text-cite_note-FDA_Herzuma_PR-11" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/fda-approves-herzuma-biosimilar-herceptin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/fda-approves-herzuma-biosimilar-herceptin'" tppabs="https://www.fda.gov/drugs/fda-approves-herzuma-biosimilar-herceptin" class="external text external">"FDA approves Herzuma as a biosimilar to Herceptin"</a>. <i>U.S. Food and Drug Administration (FDA)</i> (Press release). 18 December 2018. <a href="javascript:if(confirm('https://web.archive.org/web/20191213011107/https://www.fda.gov/drugs/fda-approves-herzuma-biosimilar-herceptin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191213011107/https://www.fda.gov/drugs/fda-approves-herzuma-biosimilar-herceptin'" tppabs="https://web.archive.org/web/20191213011107/https://www.fda.gov/drugs/fda-approves-herzuma-biosimilar-herceptin" class="external text external">Archived</a> from the original on 13 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">12 December</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-Herzuma_FDA_approval-12"> <span id="mw-reference-text-cite_note-Herzuma_FDA_approval-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761091Orig1s000TOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761091Orig1s000TOC.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761091Orig1s000TOC.cfm" class="external text external">"Drug Approval Package: Herzuma"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 7 February 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">28 July</span> 2020</span>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFBalduzziMantarroGuarneriTagliabue2014" class="citation journal cs1">Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D'Amico R (2014). <a href="javascript:if(confirm('https://air.unimi.it/bitstream/2434/237345/2/CD006242.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://air.unimi.it/bitstream/2434/237345/2/CD006242.pdf'" tppabs="https://air.unimi.it/bitstream/2434/237345/2/CD006242.pdf" class="external text external">"Trastuzumab-containing regimens for metastatic breast cancer"</a> <span class="cs1-format">(PDF)</span>. <i>Cochrane Database Syst Rev</i>. <b>6</b> (6): CD006242. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD006242.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD006242.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD006242.pub2" class="external text external">10.1002/14651858.CD006242.pub2</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464904  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464904'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464904" class="external text external">6464904</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24919460  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24919460'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24919460" class="external text external">24919460</a>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFWilcken2014" class="citation journal cs1">Wilcken, Nicholas (2014). "Treating metastatic breast cancer: The evidence for targeted therapy". <i>The Cochrane Database of Systematic Reviews</i> (6): ED000083. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.ED000083  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.ED000083'" tppabs="https://doi.org/10.1002%2F14651858.ED000083" class="external text external">10.1002/14651858.ED000083</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25032250  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25032250'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25032250" class="external text external">25032250</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFMojaTagliabueBalduzziParmelli2012" class="citation journal cs1">Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R (2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210" class="external text external">"Trastuzumab containing regimens for early breast cancer"</a>. <i>Cochrane Database Syst Rev</i>. <b>4</b> (4): CD006243. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD006243.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD006243.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD006243.pub2" class="external text external">10.1002/14651858.CD006243.pub2</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210" class="external text external">6718210</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22513938  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22513938'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22513938" class="external text external">22513938</a>.</cite></span></li><li id="cite_note-Hudis_2007-16"> <span id="mw-reference-text-cite_note-Hudis_2007-16" class="mw-reference-text"><cite id="CITEREFHudis2007" class="citation journal cs1">Hudis, CA (2007). "Trastuzumab--mechanism of action and use in clinical practice". <i>N Engl J Med</i>. <b>357</b> (1): 39–51. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMra043186  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMra043186'" tppabs="https://doi.org/10.1056%2FNEJMra043186" class="external text external">10.1056/NEJMra043186</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17611206  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17611206'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17611206" class="external text external">17611206</a>.</cite></span></li><li id="cite_note-Cochrane2012-17"> <span id="mw-reference-text-cite_note-Cochrane2012-17" class="mw-reference-text"><cite id="CITEREFMojaTagliabueBalduzzi2012" class="citation journal cs1">Moja L, Tagliabue L, Balduzzi S,  et al. (2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210" class="external text external">"Trastuzumab containing regimens for early breast cancer"</a>. <i>Cochrane Database Syst Rev</i>. <b>4</b>: CD006243. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD006243.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD006243.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD006243.pub2" class="external text external">10.1002/14651858.CD006243.pub2</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210" class="external text external">6718210</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22513938  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22513938'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22513938" class="external text external">22513938</a>.</cite></span></li><li id="cite_note-TanSwain-18"> <span id="mw-reference-text-cite_note-TanSwain-18" class="mw-reference-text"><cite id="CITEREFTanSwain_SM2002" class="citation journal cs1">Tan, AR; Swain SM (2002). "Ongoing adjuvant trials with trastuzumab in breast cancer". <i>Seminars in Oncology</i>. <b>30</b> (5 Suppl 16): 54–64. doi:<a href="javascript:if(confirm('https://doi.org/10.1053%2Fj.seminoncol.2003.08.008  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1053%2Fj.seminoncol.2003.08.008'" tppabs="https://doi.org/10.1053%2Fj.seminoncol.2003.08.008" class="external text external">10.1053/j.seminoncol.2003.08.008</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14613027  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14613027'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14613027" class="external text external">14613027</a>.</cite></span></li><li id="cite_note-NahtaEsteva-19"> <span id="mw-reference-text-cite_note-NahtaEsteva-19" class="mw-reference-text"><cite id="CITEREFNahtaEsteva1_FJ2003" class="citation journal cs1">Nahta, R; Esteva1 FJ (2003). "HER-2-Targeted Therapy –Lessons Learned and Future Directions". <i>Clinical Cancer Research</i>. <b>9</b> (14): 5078–84. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14613984  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14613984'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14613984" class="external text external">14613984</a>.</cite></span></li><li id="cite_note-YuHung-20"> <span id="mw-reference-text-cite_note-YuHung-20" class="mw-reference-text"><cite id="CITEREFYuHung_M2000" class="citation journal cs1">Yu, D; Hung M (2000). <a href="javascript:if(confirm('https://doi.org/10.1038/sj.onc.1203972  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/sj.onc.1203972'" tppabs="https://doi.org/10.1038/sj.onc.1203972" class="external text external">"Overexpression of ErbB2 in cancer and ErbB2-targeting strategies"</a>. <i>Oncogene</i>. <b>19</b> (53): 6115–6121. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.onc.1203972  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.onc.1203972'" tppabs="https://doi.org/10.1038%2Fsj.onc.1203972" class="external text external">10.1038/sj.onc.1203972</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11156524  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11156524'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11156524" class="external text external">11156524</a>.</cite></span></li><li id="cite_note-Le_2005-21"> <span id="mw-reference-text-cite_note-Le_2005-21" class="mw-reference-text"><cite id="CITEREFXF_LeFranz_PrueferRobert_Bast.2005" class="citation journal cs1">XF Le; Franz Pruefer; Robert Bast. (2005). <a href="javascript:if(confirm('https://doi.org/10.4161/cc.4.1.1360  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4161/cc.4.1.1360'" tppabs="https://doi.org/10.4161/cc.4.1.1360" class="external text external">"HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways"</a>. <i>Cell Cycle</i>. <b>4</b> (1): 87–95. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.4161%2Fcc.4.1.1360  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4161%2Fcc.4.1.1360'" tppabs="https://doi.org/10.4161%2Fcc.4.1.1360" class="external text external">10.4161/cc.4.1.1360</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15611642  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15611642'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15611642" class="external text external">15611642</a>.</cite></span></li><li id="cite_note-Kute-22"> <span id="mw-reference-text-cite_note-Kute-22" class="mw-reference-text"><cite id="CITEREFKuteLack_CMWillingham_MBishwokama_B2004" class="citation journal cs1">Kute, T; Lack CM; Willingham M; Bishwokama B; Williams H; Barrett K; Mitchell T; Vaughn JP (2004). "Development of Herceptin resistance in breast cancer cells". <i>Cytometry</i>. <b>57A</b> (2): 86–93. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fcyto.a.10095  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fcyto.a.10095'" tppabs="https://doi.org/10.1002%2Fcyto.a.10095" class="external text external">10.1002/cyto.a.10095</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14750129  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14750129'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14750129" class="external text external">14750129</a>.</cite></span></li><li id="cite_note-Romond-23"> <span id="mw-reference-text-cite_note-Romond-23" class="mw-reference-text"><cite id="CITEREFRomondPerez_EABryant_J2005" class="citation journal cs1">Romond, EH; Perez EA; Bryant J;  et al. (2005). "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer". <i>New England Journal of Medicine</i>. <b>353</b> (16): 1673–1684. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa052122  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa052122'" tppabs="https://doi.org/10.1056%2FNEJMoa052122" class="external text external">10.1056/NEJMoa052122</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16236738  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16236738'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16236738" class="external text external">16236738</a>.</cite></span></li><li id="cite_note-Piccart-24"> <span id="mw-reference-text-cite_note-Piccart-24" class="mw-reference-text"><cite id="CITEREFPiccart-Gebhart_MJProcter_MLeyland-Jones_B2005" class="citation journal cs1">Piccart-Gebhart MJ, MJ; Procter M; Leyland-Jones B;  et al. (2005). "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer". <i>New England Journal of Medicine</i>. <b>353</b> (16): 1659–1672. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa052306  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa052306'" tppabs="https://doi.org/10.1056%2FNEJMoa052306" class="external text external">10.1056/NEJMoa052306</a>. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10722%2F251817  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10722%2F251817'" tppabs="https://hdl.handle.net/10722%2F251817" class="external text external">10722/251817</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16236737  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16236737'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16236737" class="external text external">16236737</a>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFJoensuuKellokumpu-LehtinenBono2006" class="citation journal cs1">Joensuu H, Kellokumpu-Lehtinen PL, Bono P,  et al. (2006). <a href="javascript:if(confirm('https://semanticscholar.org/paper/7e530a31d01bcdaacb8b7d27744c8e2e18f847c8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://semanticscholar.org/paper/7e530a31d01bcdaacb8b7d27744c8e2e18f847c8'" tppabs="https://semanticscholar.org/paper/7e530a31d01bcdaacb8b7d27744c8e2e18f847c8" class="external text external">"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer"</a>. <i>N Engl J Med</i>. <b>354</b> (8): 809–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa053028  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa053028'" tppabs="https://doi.org/10.1056%2FNEJMoa053028" class="external text external">10.1056/NEJMoa053028</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16495393  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16495393'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16495393" class="external text external">16495393</a>.</cite></span></li><li id="cite_note-Metcalfe-26"> <span id="mw-reference-text-cite_note-Metcalfe-26" class="mw-reference-text"><cite id="CITEREFMetcalfeEvans_JPriest_G.2007" class="citation journal cs1">Metcalfe, S; Evans J; Priest G. (2007). "PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer". <i>N Z Med J</i>. <b>120</b> (1256): 1U2593. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17589560  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17589560'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17589560" class="external text external">17589560</a>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.beehive.govt.nz/release/12-month-herceptin-treatment-now-available  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.beehive.govt.nz/release/12-month-herceptin-treatment-now-available'" tppabs="http://www.beehive.govt.nz/release/12-month-herceptin-treatment-now-available" class="external text external">"12-month Herceptin treatment now available"</a>. New Zealand Government. <a href="javascript:if(confirm('https://web.archive.org/web/20170120122328/https://www.beehive.govt.nz/release/12-month-herceptin-treatment-now-available  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170120122328/https://www.beehive.govt.nz/release/12-month-herceptin-treatment-now-available'" tppabs="https://web.archive.org/web/20170120122328/https://www.beehive.govt.nz/release/12-month-herceptin-treatment-now-available" class="external text external">Archived</a> from the original on 20 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">2 May</span> 2017</span>.</cite></span></li><li id="cite_note-Breast_Cancer_Care-28"> <span id="mw-reference-text-cite_note-Breast_Cancer_Care-28" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf'" tppabs="http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf" class="external text external">"Breast Cancer Care Trastuzumab factsheet"</a> <span class="cs1-format">(PDF)</span>. Breast Cancer Care. <a href="javascript:if(confirm('https://web.archive.org/web/20131023061716/http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131023061716/http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf'" tppabs="https://web.archive.org/web/20131023061716/http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 23 October 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">22 October</span> 2013</span>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite id="CITEREFSeidman,_A2002" class="citation journal cs1">Seidman, A;  et al. (2002). "Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience". <i>Journal of Clinical Oncology</i>. <b>20</b> (5): 1215–1221. doi:<a href="javascript:if(confirm('https://doi.org/10.1200%2FJCO.20.5.1215  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1200%2FJCO.20.5.1215'" tppabs="https://doi.org/10.1200%2FJCO.20.5.1215" class="external text external">10.1200/JCO.20.5.1215</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11870163  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11870163'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11870163" class="external text external">11870163</a>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite id="CITEREFvan_Hasselt2011" class="citation journal cs1">van Hasselt;  et al. (2011). "Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity". <i>Clin Pharmacol Ther</i>. <b>90</b> (1): 126–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fclpt.2011.74  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fclpt.2011.74'" tppabs="https://doi.org/10.1038%2Fclpt.2011.74" class="external text external">10.1038/clpt.2011.74</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21633346  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21633346'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21633346" class="external text external">21633346</a>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text">Zeglinski, M., Ludke, A., Jassal, D. S. &amp; Singal, P. K. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Exp. Clin. Cardiol. 16, 70-74 (2011)</span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf'" tppabs="http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf" class="external text external">"Breast Cancer Care Trastuzumab factsheet"</a> <span class="cs1-format">(PDF)</span>. <a href="javascript:if(confirm('https://web.archive.org/web/20131023061716/http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131023061716/http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf'" tppabs="https://web.archive.org/web/20131023061716/http://www2.breastcancercare.org.uk/sites/default/files/bcc41_trastuzumab_2011.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 23 October 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">22 October</span> 2013</span>.</cite></span></li><li id="cite_note-Bange-33"> <span id="mw-reference-text-cite_note-Bange-33" class="mw-reference-text"><cite id="CITEREFBangeZwick_EUllrich_A.2001" class="citation journal cs1">Bange, J; Zwick E; Ullrich A. (2001). "Molecular targets for breast cancer therapy and prevention". <i>Nature Medicine</i>. <b>7</b> (5): 548–552. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2F87872  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2F87872'" tppabs="https://doi.org/10.1038%2F87872" class="external text external">10.1038/87872</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11329054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11329054'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11329054" class="external text external">11329054</a>.</cite></span></li><li id="cite_note-cancer-34"> <span id="mw-reference-text-cite_note-cancer-34" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.cancer.gov/cancertopics/understandingcancer/targetedtherapies/breastcancer_htmlcourse/page3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cancer.gov/cancertopics/understandingcancer/targetedtherapies/breastcancer_htmlcourse/page3'" tppabs="http://www.cancer.gov/cancertopics/understandingcancer/targetedtherapies/breastcancer_htmlcourse/page3" class="external text external">"Targeted Therapies for Breast Cancer Tutorial"</a>. <i>National Cancer Institute</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20110329143648/http://www.cancer.gov/cancertopics/understandingcancer/targetedtherapies/breastcancer_htmlcourse/page3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110329143648/http://www.cancer.gov/cancertopics/understandingcancer/targetedtherapies/breastcancer_htmlcourse/page3'" tppabs="https://web.archive.org/web/20110329143648/http://www.cancer.gov/cancertopics/understandingcancer/targetedtherapies/breastcancer_htmlcourse/page3" class="external text external">Archived</a> from the original on 29 March 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">19 April</span> 2011</span>.</cite></span></li><li id="cite_note-Feldman-35"> <span id="mw-reference-text-cite_note-Feldman-35" class="mw-reference-text"><cite id="CITEREFFeldmanKoch,_W_JForce,_T_L2007" class="citation journal cs1">Feldman, A M; Koch, W J; Force, T L (28 March 2007). "Developing Strategies to Link Basic Cardiovascular Sciences with Clinical Drug Development: Another Opportunity for Translational Sciences". <i>Clinical Pharmacology &amp; Therapeutics</i>. <b>81</b> (6): 887–892. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.clpt.6100160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.clpt.6100160'" tppabs="https://doi.org/10.1038%2Fsj.clpt.6100160" class="external text external">10.1038/sj.clpt.6100160</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17392727  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17392727'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17392727" class="external text external">17392727</a>.</cite></span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><cite id="CITEREFWiner" class="citation web cs1">Winer, Eric. <a href="javascript:if(confirm('http://www.medscape.org/viewarticle/557474  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medscape.org/viewarticle/557474'" tppabs="http://www.medscape.org/viewarticle/557474" class="external text external">"HER2 Disease in the Metastatic and Adjuvant Settings"</a>. <i>Medscape Education</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20110410233213/http://www.medscape.org/viewarticle/557474  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110410233213/http://www.medscape.org/viewarticle/557474'" tppabs="https://web.archive.org/web/20110410233213/http://www.medscape.org/viewarticle/557474" class="external text external">Archived</a> from the original on 10 April 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">20 April</span> 2011</span>.</cite></span></li><li id="cite_note-Menard-37"> <span id="mw-reference-text-cite_note-Menard-37" class="mw-reference-text"><cite id="CITEREFMénardPupa_SMCampiglio_MTagliabue_E2003" class="citation journal cs1">Ménard, S; Pupa SM; Campiglio M; Tagliabue E (2003). <a href="javascript:if(confirm('https://doi.org/10.1038/sj.onc.1206779  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/sj.onc.1206779'" tppabs="https://doi.org/10.1038/sj.onc.1206779" class="external text external">"Biologic and therapeutic role of HER2 in cancer"</a>. <i>Oncogene</i>. <b>22</b> (42): 6570–6578. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.onc.1206779  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.onc.1206779'" tppabs="https://doi.org/10.1038%2Fsj.onc.1206779" class="external text external">10.1038/sj.onc.1206779</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14528282  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14528282'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14528282" class="external text external">14528282</a>.</cite></span></li><li id="cite_note-38"> <span id="mw-reference-text-cite_note-38" class="mw-reference-text"><cite id="CITEREFChoMasonRamyarStanley2003" class="citation journal cs1">Cho, Hyun-Soo; Mason, Karen; Ramyar, Kasra X.; Stanley, Ann Marie; Gabelli, Sandra B.; Denney, Dan W.; Leahy, Daniel J. (2003). "Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab". <i>Nature</i>. <b>421</b> (6924): 756–760. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2003Natur.421..756C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2003Natur.421..756C'" tppabs="https://ui.adsabs.harvard.edu/abs/2003Natur.421..756C" class="external text external">2003Natur.421..756C</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnature01392  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnature01392'" tppabs="https://doi.org/10.1038%2Fnature01392" class="external text external">10.1038/nature01392</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12610629  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12610629'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12610629" class="external text external">12610629</a>.</cite></span></li><li id="cite_note-39"> <span id="mw-reference-text-cite_note-39" class="mw-reference-text"><cite id="CITEREFDrebinSternLinkWeinberg1984" class="citation journal cs1">Drebin, J. A.; Stern, D. F.; Link, V. C.; Weinberg, R. A.; Greene, M. I. (6–12 December 1984). "Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene". <i>Nature</i>. <b>312</b> (5994): 545–548. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/1984Natur.312..545D  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/1984Natur.312..545D'" tppabs="https://ui.adsabs.harvard.edu/abs/1984Natur.312..545D" class="external text external">1984Natur.312..545D</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2F312545a0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2F312545a0'" tppabs="https://doi.org/10.1038%2F312545a0" class="external text external">10.1038/312545a0</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0028-0836  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0028-0836'" tppabs="https://www.worldcat.org/issn/0028-0836" class="external text external">0028-0836</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6504162  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6504162'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6504162" class="external text external">6504162</a>.</cite></span></li><li id="cite_note-Albenall-40"> <span id="mw-reference-text-cite_note-Albenall-40" class="mw-reference-text"><cite id="CITEREFAlbanellCodony_JRovira_AMellado_B2003" class="citation book cs1">Albanell, J; Codony J; Rovira A; Mellado B; Gascon P. (2003). <i>Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4</i>. Advances in Experimental Medicine and Biology. <b>532</b>. pp.<span>&nbsp;</span>253–268. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-1-4615-0081-0_21  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-1-4615-0081-0_21'" tppabs="https://doi.org/10.1007%2F978-1-4615-0081-0_21" class="external text external">10.1007/978-1-4615-0081-0_21</a>. ISBN<span>&nbsp;</span><bdi>978-0-306-47762-1</bdi>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12908564  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12908564'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12908564" class="external text external">12908564</a>.</cite></span></li><li id="cite_note-41"> <span id="mw-reference-text-cite_note-41" class="mw-reference-text"><cite id="CITEREFClynesTowersPrestaRavetch2000" class="citation journal cs1">Clynes, RA; Towers, TL; Presta, LG; Ravetch, JV (2000). "Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets". <i>Nat Med</i>. <b>6</b> (4): 443–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2F74704  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2F74704'" tppabs="https://doi.org/10.1038%2F74704" class="external text external">10.1038/74704</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10742152  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10742152'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10742152" class="external text external">10742152</a>.</cite></span></li><li id="cite_note-Jennings-42"> <span id="mw-reference-text-cite_note-Jennings-42" class="mw-reference-text"><cite id="CITEREFJenningsHadfield_JEWorsley_SDGirling_A1997" class="citation journal cs1">Jennings, B; Hadfield JE; Worsley SD; Girling A; Willis G. (1997). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC379641  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC379641'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC379641" class="external text external">"A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer"</a>. <i>Molecular Pathology</i>. <b>50</b> (5): 254–256. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fmp.50.5.254  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fmp.50.5.254'" tppabs="https://doi.org/10.1136%2Fmp.50.5.254" class="external text external">10.1136/mp.50.5.254</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC379641  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC379641'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC379641" class="external text external">379641</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9497915  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9497915'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9497915" class="external text external">9497915</a>.</cite></span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text"><cite id="CITEREFCurtisShahChinTurashvili2012" class="citation journal cs1">Curtis, C; Shah, SP; Chin, SF; Turashvili, G; Rueda, OM; Dunning, MJ; Speed, D; Lynch, AG; Samarajiwa, S; Yuan, Y; Gräf, S; Ha, G; Haffari, G; Bashashati, A; Russell, R; McKinney, S; METABRIC, Group; Langerød, A; Green, A; Provenzano, E; Wishart, G; Pinder, S; Watson, P; Markowetz, F; Murphy, L; Ellis, I; Purushotham, A; Børresen-Dale, AL; Brenton, JD; Tavaré, S; Caldas, C; Aparicio, S (18 April 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440846  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440846'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440846" class="external text external">"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups"</a>. <i>Nature</i>. <b>486</b> (7403): 346–52. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2012Natur.486..346.  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2012Natur.486..346.'" tppabs="https://ui.adsabs.harvard.edu/abs/2012Natur.486..346." class="external text external">2012Natur.486..346.</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnature10983  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnature10983'" tppabs="https://doi.org/10.1038%2Fnature10983" class="external text external">10.1038/nature10983</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440846  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440846'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440846" class="external text external">3440846</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22522925  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22522925'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22522925" class="external text external">22522925</a>.</cite></span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.dakousa.com/index/prod_search/prod_baseproducts.htm?productareaid=1&productgroupid=3&productsubgroupid=1003000  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.dakousa.com/index/prod_search/prod_baseproducts.htm?productareaid=1&productgroupid=3&productsubgroupid=1003000'" tppabs="http://www.dakousa.com/index/prod_search/prod_baseproducts.htm?productareaid=1&productgroupid=3&productsubgroupid=1003000" class="external text external">"Archived copy"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20090523140046/http://www.dakousa.com/index/prod_search/prod_baseproducts.htm?productareaid=1&productgroupid=3&productsubgroupid=1003000  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090523140046/http://www.dakousa.com/index/prod_search/prod_baseproducts.htm?productareaid=1&productgroupid=3&productsubgroupid=1003000'" tppabs="https://web.archive.org/web/20090523140046/http://www.dakousa.com/index/prod_search/prod_baseproducts.htm?productareaid=1&productgroupid=3&productsubgroupid=1003000" class="external text external">Archived</a> from the original on 23 May 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2008</span>.</cite><span class="cs1-maint citation-comment">CS1 maint: archived copy as title (link)</span></span></li><li id="cite_note-ventanamed1-45"> <span id="mw-reference-text-cite_note-ventanamed1-45" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.ventanamed.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ventanamed.com/'" tppabs="http://www.ventanamed.com/" class="external text external">"ventanamed.com"</a>. ventanamed.com. 25 May 2012. <a href="javascript:if(confirm('https://web.archive.org/web/20111127211754/http://www.ventanamed.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20111127211754/http://www.ventanamed.com/'" tppabs="https://web.archive.org/web/20111127211754/http://www.ventanamed.com/" class="external text external">Archived</a> from the original on 27 November 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">16 June</span> 2013</span>.</cite></span></li><li id="cite_note-46"> <span id="mw-reference-text-cite_note-46" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120325110438/http://www.bioportfolio.com/news/article/711287/Ventana-Medical-Systems-Inc-Receives-Fda-Approval-For-The-First-Fully-Automated.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120325110438/http://www.bioportfolio.com/news/article/711287/Ventana-Medical-Systems-Inc-Receives-Fda-Approval-For-The-First-Fully-Automated.html'" tppabs="https://web.archive.org/web/20120325110438/http://www.bioportfolio.com/news/article/711287/Ventana-Medical-Systems-Inc-Receives-Fda-Approval-For-The-First-Fully-Automated.html" class="external text external">"Ventana Medical Systems, Inc. Receives FDA Approval for the First Fully Automated Diagnostic Assay for HER2 Gene Status Determination in Breast Cancer Patients"</a>. BioPortfolio.com. 14 June 2011. Archived from <a href="javascript:if(confirm('http://www.bioportfolio.com/news/article/711287/Ventana-Medical-Systems-Inc-Receives-Fda-Approval-For-The-First-Fully-Automated.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.bioportfolio.com/news/article/711287/Ventana-Medical-Systems-Inc-Receives-Fda-Approval-For-The-First-Fully-Automated.html'" tppabs="http://www.bioportfolio.com/news/article/711287/Ventana-Medical-Systems-Inc-Receives-Fda-Approval-For-The-First-Fully-Automated.html" class="external text external">the original</a> on 25 March 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">6 January</span> 2013</span>.</cite></span></li><li id="cite_note-47"> <span id="mw-reference-text-cite_note-47" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40271  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40271'" tppabs="http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40271" class="external text external">"Dual color dual hapten HER2 genotyping for breast biopsy specimens (DDISH): Concordance with fluorescence in situ hybridization (FISH)"</a>. ASCO. 6 October 2009. <a href="javascript:if(confirm('https://web.archive.org/web/20120323004623/http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40271  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120323004623/http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40271'" tppabs="https://web.archive.org/web/20120323004623/http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=70&abstractID=40271" class="external text external">Archived</a> from the original on 23 March 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">6 January</span> 2013</span>.</cite></span></li><li id="cite_note-48"> <span id="mw-reference-text-cite_note-48" class="mw-reference-text"><cite id="CITEREFAhmad_S2014" class="citation journal cs1">Ahmad S (2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967150  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967150'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967150" class="external text external">"Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients"</a>. <i>Nature</i>. <b>4</b>: 4483. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2014NatSR...4E4483A  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2014NatSR...4E4483A'" tppabs="https://ui.adsabs.harvard.edu/abs/2014NatSR...4E4483A" class="external text external">2014NatSR...4E4483A</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fsrep04483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsrep04483'" tppabs="https://doi.org/10.1038%2Fsrep04483" class="external text external">10.1038/srep04483</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967150  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967150'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967150" class="external text external">3967150</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24670875  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24670875'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24670875" class="external text external">24670875</a>.</cite></span></li><li id="cite_note-49"> <span id="mw-reference-text-cite_note-49" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.cancer.ucla.edu/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cancer.ucla.edu/'" tppabs="http://www.cancer.ucla.edu/" class="external text external">"cancer.ucla.edu"</a>. cancer.ucla.edu. <a href="javascript:if(confirm('https://web.archive.org/web/20130611071654/http://www.cancer.ucla.edu/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130611071654/http://www.cancer.ucla.edu/'" tppabs="https://web.archive.org/web/20130611071654/http://www.cancer.ucla.edu/" class="external text external">Archived</a> from the original on 11 June 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">16 June</span> 2013</span>.</cite></span></li><li id="cite_note-50"> <span id="mw-reference-text-cite_note-50" class="mw-reference-text"><cite id="CITEREFSchechterSternVaidyanathanDecker1984" class="citation journal cs1">Schechter, A. L.; Stern, D. F.; Vaidyanathan, L.; Decker, S. J.; Drebin, J. A.; Greene, M. I.; Weinberg, R. A. (6–12 December 1984). "The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen". <i>Nature</i>. <b>312</b> (5994): 513–516. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2F312513a0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2F312513a0'" tppabs="https://doi.org/10.1038%2F312513a0" class="external text external">10.1038/312513a0</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0028-0836  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0028-0836'" tppabs="https://www.worldcat.org/issn/0028-0836" class="external text external">0028-0836</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6095109  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6095109'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6095109" class="external text external">6095109</a>.</cite></span></li><li id="cite_note-51"> <span id="mw-reference-text-cite_note-51" class="mw-reference-text"><cite id="CITEREFDrebinLinkWeinbergGreene1986" class="citation journal cs1">Drebin, J. A.; Link, V. C.; Weinberg, R. A.; Greene, M. I. (December 1986). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC387088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC387088'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC387088" class="external text external">"Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen"</a>. <i>Proceedings of the National Academy of Sciences of the United States of America</i>. <b>83</b> (23): 9129–9133. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/1986PNAS...83.9129D  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/1986PNAS...83.9129D'" tppabs="https://ui.adsabs.harvard.edu/abs/1986PNAS...83.9129D" class="external text external">1986PNAS...83.9129D</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1073%2Fpnas.83.23.9129  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1073%2Fpnas.83.23.9129'" tppabs="https://doi.org/10.1073%2Fpnas.83.23.9129" class="external text external">10.1073/pnas.83.23.9129</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0027-8424  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0027-8424'" tppabs="https://www.worldcat.org/issn/0027-8424" class="external text external">0027-8424</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC387088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC387088'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC387088" class="external text external">387088</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3466178  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3466178'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3466178" class="external text external">3466178</a>.</cite></span></li><li id="cite_note-52"> <span id="mw-reference-text-cite_note-52" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.gene.com/media/press-releases/4763/1998-09-25/biotechnology-breakthrough-in-breast-can  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.gene.com/media/press-releases/4763/1998-09-25/biotechnology-breakthrough-in-breast-can'" tppabs="http://www.gene.com/media/press-releases/4763/1998-09-25/biotechnology-breakthrough-in-breast-can" class="external text external">"Biotechnology Breakthrough In Breast Cancer Wins FDA Approval"</a>. Genentech. 25 September 1998. <a href="javascript:if(confirm('https://web.archive.org/web/20160701223424/http://www.gene.com/media/press-releases/4763/1998-09-25/biotechnology-breakthrough-in-breast-can  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160701223424/http://www.gene.com/media/press-releases/4763/1998-09-25/biotechnology-breakthrough-in-breast-can'" tppabs="https://web.archive.org/web/20160701223424/http://www.gene.com/media/press-releases/4763/1998-09-25/biotechnology-breakthrough-in-breast-can" class="external text external">Archived</a> from the original on 1 July 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">30 May</span> 2016</span>.</cite></span></li><li id="cite_note-53"> <span id="mw-reference-text-cite_note-53" class="mw-reference-text"><cite id="CITEREFAltman,_Lawrence1998" class="citation web cs1">Altman, Lawrence (18 May 1998). <a href="javascript:if(confirm('https://www.nytimes.com/1998/05/18/us/drug-is-shown-to-shrink-tumors-in-breast-cancer-characterized-by-gene-defect.html?pagewanted=all  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/1998/05/18/us/drug-is-shown-to-shrink-tumors-in-breast-cancer-characterized-by-gene-defect.html?pagewanted=all'" tppabs="https://www.nytimes.com/1998/05/18/us/drug-is-shown-to-shrink-tumors-in-breast-cancer-characterized-by-gene-defect.html?pagewanted=all" class="external text external">"Drug Is Shown to Shrink Tumors in Breast Cancer Characterized by Gene Defect"</a>. <i>New York Times</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20160630214956/http://www.nytimes.com/1998/05/18/us/drug-is-shown-to-shrink-tumors-in-breast-cancer-characterized-by-gene-defect.html?pagewanted=all  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160630214956/http://www.nytimes.com/1998/05/18/us/drug-is-shown-to-shrink-tumors-in-breast-cancer-characterized-by-gene-defect.html?pagewanted=all'" tppabs="https://web.archive.org/web/20160630214956/http://www.nytimes.com/1998/05/18/us/drug-is-shown-to-shrink-tumors-in-breast-cancer-characterized-by-gene-defect.html?pagewanted=all" class="external text external">Archived</a> from the original on 30 June 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">30 May</span> 2016</span>.</cite></span></li><li id="cite_note-54"> <span id="mw-reference-text-cite_note-54" class="mw-reference-text"><cite id="CITEREFPalmer2017" class="citation news cs1">Palmer, Eric (3 March 2017). <a href="javascript:if(confirm('http://www.fiercepharma.com/pharma/mylan-and-biocon-finally-win-right-to-sell-herceptin-biosim-india-even-as-they-have-taken-it  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fiercepharma.com/pharma/mylan-and-biocon-finally-win-right-to-sell-herceptin-biosim-india-even-as-they-have-taken-it'" tppabs="http://www.fiercepharma.com/pharma/mylan-and-biocon-finally-win-right-to-sell-herceptin-biosim-india-even-as-they-have-taken-it" class="external text external">"Mylan and Biocon finally win right to sell Herceptin biosim in India even as they have taken it to U.S. and EU"</a>. <i>FiercePharma</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908112222/http://www.fiercepharma.com/pharma/mylan-and-biocon-finally-win-right-to-sell-herceptin-biosim-india-even-as-they-have-taken-it  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908112222/http://www.fiercepharma.com/pharma/mylan-and-biocon-finally-win-right-to-sell-herceptin-biosim-india-even-as-they-have-taken-it'" tppabs="https://web.archive.org/web/20170908112222/http://www.fiercepharma.com/pharma/mylan-and-biocon-finally-win-right-to-sell-herceptin-biosim-india-even-as-they-have-taken-it" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-55"> <span id="mw-reference-text-cite_note-55" class="mw-reference-text"><cite id="CITEREFFleck_L2006" class="citation journal cs1">Fleck L (2006). "The costs of caring: Who pays? Who profits? Who panders?". <i>Hastings Cent Rep</i>. <b>36</b> (3): 13–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1353%2Fhcr.2006.0040  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1353%2Fhcr.2006.0040'" tppabs="https://doi.org/10.1353%2Fhcr.2006.0040" class="external text external">10.1353/hcr.2006.0040</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16776017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16776017'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16776017" class="external text external">16776017</a>.</cite></span></li><li id="cite_note-56"> <span id="mw-reference-text-cite_note-56" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20090912045429/http://www.health.gov.au/internet/main/publishing.nsf/Content/herceptin-govtdecision.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090912045429/http://www.health.gov.au/internet/main/publishing.nsf/Content/herceptin-govtdecision.htm'" tppabs="https://web.archive.org/web/20090912045429/http://www.health.gov.au/internet/main/publishing.nsf/Content/herceptin-govtdecision.htm" class="external text external">"Listing of Herceptin on PBS"</a>. Australian Government, Dept of Health and Ageing. 1 October 2006. Archived from <a href="javascript:if(confirm('http://www.health.gov.au/internet/main/publishing.nsf/Content/herceptin-govtdecision.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.health.gov.au/internet/main/publishing.nsf/Content/herceptin-govtdecision.htm'" tppabs="http://www.health.gov.au/internet/main/publishing.nsf/Content/herceptin-govtdecision.htm" class="external text external">the original</a> on 12 September 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">6 August</span> 2009</span>.</cite></span></li><li id="cite_note-57"> <span id="mw-reference-text-cite_note-57" class="mw-reference-text">Australian Government, Dept of Health and Ageing "Listing of Herceptin on PBS", 2006-10-1. <cite class="citation web cs1"><a href="javascript:if(confirm('http://www.pbs.gov.au/info/news/2006/10/listing-of-herceptin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pbs.gov.au/info/news/2006/10/listing-of-herceptin'" tppabs="http://www.pbs.gov.au/info/news/2006/10/listing-of-herceptin" class="external text external">"Pharmaceutical Benefits Scheme (PBS) <span>|</span> Listing of Herceptin on the PBS"</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20131023114913/http://www.pbs.gov.au/info/news/2006/10/listing-of-herceptin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131023114913/http://www.pbs.gov.au/info/news/2006/10/listing-of-herceptin'" tppabs="https://web.archive.org/web/20131023114913/http://www.pbs.gov.au/info/news/2006/10/listing-of-herceptin" class="external text external">Archived</a> from the original on 23 October 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">20 October</span> 2013</span>.</cite></span></li><li id="cite_note-58"> <span id="mw-reference-text-cite_note-58" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://articles.economictimes.indiatimes.com/2012-03-02/news/31117087_1_emcure-pharmaceuticals-anti-hiv-drugs-emcure-signs-deal  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://articles.economictimes.indiatimes.com/2012-03-02/news/31117087_1_emcure-pharmaceuticals-anti-hiv-drugs-emcure-signs-deal'" tppabs="http://articles.economictimes.indiatimes.com/2012-03-02/news/31117087_1_emcure-pharmaceuticals-anti-hiv-drugs-emcure-signs-deal" class="external text external">"Emcure signs deal to manufacture Roche's anti-cancer drugs"</a>. <i>The Times Of India</i>. 2 March 2012.</cite></span></li><li id="cite_note-Time_2014-59"> <span id="mw-reference-text-cite_note-Time_2014-59" class="mw-reference-text"><cite id="CITEREFSaporito,_Bill2014" class="citation web cs1">Saporito, Bill (27 October 2014). <a href="javascript:if(confirm('http://time.com/3541484/cancer-drug-price-hikes/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://time.com/3541484/cancer-drug-price-hikes/'" tppabs="http://time.com/3541484/cancer-drug-price-hikes/" class="external text external">"Hospitals Furious at Cancer-Drug Price Hikes"</a>. <i>Time</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20151020062334/http://time.com/3541484/cancer-drug-price-hikes/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151020062334/http://time.com/3541484/cancer-drug-price-hikes/'" tppabs="https://web.archive.org/web/20151020062334/http://time.com/3541484/cancer-drug-price-hikes/" class="external text external">Archived</a> from the original on 20 October 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">26 October</span> 2015</span>.</cite></span></li><li id="cite_note-60"> <span id="mw-reference-text-cite_note-60" class="mw-reference-text">Cynthia A. Challener (1 April 2014). <a href="javascript:if(confirm('http://www.biopharminternational.com/monoclonal-antibodies-key-unlocking-biosimilars-market  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.biopharminternational.com/monoclonal-antibodies-key-unlocking-biosimilars-market'" tppabs="http://www.biopharminternational.com/monoclonal-antibodies-key-unlocking-biosimilars-market" class="external text external">Monoclonal Antibodies Key to Unlocking the Biosimilars Market</a> <a href="javascript:if(confirm('https://web.archive.org/web/20160301220108/http://www.biopharminternational.com/monoclonal-antibodies-key-unlocking-biosimilars-market  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160301220108/http://www.biopharminternational.com/monoclonal-antibodies-key-unlocking-biosimilars-market'" tppabs="https://web.archive.org/web/20160301220108/http://www.biopharminternational.com/monoclonal-antibodies-key-unlocking-biosimilars-market" class="external text external">Archived</a><span> 2016-03-01 at the </span>Wayback Machine. <i>BioPharm international.com</i> <i>27</i> (4).</span></li><li id="cite_note-61"> <span id="mw-reference-text-cite_note-61" class="mw-reference-text">Dominik Feldges (February 2016). <a href="javascript:if(confirm('http://www.nzz.ch/wirtschaft/kommentare/iraner-kopieren-roche-1.18697650?extcid=Newsletter_19022016_Top-News_am_Morgen  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nzz.ch/wirtschaft/kommentare/iraner-kopieren-roche-1.18697650?extcid=Newsletter_19022016_Top-News_am_Morgen'" tppabs="http://www.nzz.ch/wirtschaft/kommentare/iraner-kopieren-roche-1.18697650?extcid=Newsletter_19022016_Top-News_am_Morgen" class="external text external">Brustkrebspräparat Herceptin im Fokus</a> <a href="javascript:if(confirm('https://web.archive.org/web/20160302060434/http://www.nzz.ch/wirtschaft/kommentare/iraner-kopieren-roche-1.18697650?extcid=Newsletter_19022016_Top-News_am_Morgen  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160302060434/http://www.nzz.ch/wirtschaft/kommentare/iraner-kopieren-roche-1.18697650?extcid=Newsletter_19022016_Top-News_am_Morgen'" tppabs="https://web.archive.org/web/20160302060434/http://www.nzz.ch/wirtschaft/kommentare/iraner-kopieren-roche-1.18697650?extcid=Newsletter_19022016_Top-News_am_Morgen" class="external text external">Archived</a><span> 2016-03-02 at the </span>Wayback Machine (in German). <i>Neue Zürcher Zeitung</i> (Wirtschaft). Retrieved 19 February 2016.</span></li><li id="cite_note-62"> <span id="mw-reference-text-cite_note-62" class="mw-reference-text"><a href="javascript:if(confirm('http://www.cancernetwork.com/asco-2016-breast-cancer/biosimilar-matches-trastuzumab-metastatic-her2-positive-breast-cancer  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cancernetwork.com/asco-2016-breast-cancer/biosimilar-matches-trastuzumab-metastatic-her2-positive-breast-cancer'" tppabs="http://www.cancernetwork.com/asco-2016-breast-cancer/biosimilar-matches-trastuzumab-metastatic-her2-positive-breast-cancer" class="external text external">Biosimilar Matches Trastuzumab in Metastatic HER2-Positive Breast Cancer. June 2016</a> <a href="javascript:if(confirm('https://web.archive.org/web/20160611224312/http://www.cancernetwork.com/asco-2016-breast-cancer/biosimilar-matches-trastuzumab-metastatic-her2-positive-breast-cancer  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160611224312/http://www.cancernetwork.com/asco-2016-breast-cancer/biosimilar-matches-trastuzumab-metastatic-her2-positive-breast-cancer'" tppabs="https://web.archive.org/web/20160611224312/http://www.cancernetwork.com/asco-2016-breast-cancer/biosimilar-matches-trastuzumab-metastatic-her2-positive-breast-cancer" class="external text external">Archived</a><span> 2016-06-11 at the </span>Wayback Machine</span></li><li id="cite_note-63"> <span id="mw-reference-text-cite_note-63" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ogivri-biosimilar-herceptin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ogivri-biosimilar-herceptin'" tppabs="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ogivri-biosimilar-herceptin" class="external text external">"FDA approves Ogivri as a biosimilar to Herceptin"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 1 December 2017. <a href="javascript:if(confirm('https://web.archive.org/web/20191203044428/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ogivri-biosimilar-herceptin  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191203044428/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ogivri-biosimilar-herceptin'" tppabs="https://web.archive.org/web/20191203044428/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ogivri-biosimilar-herceptin" class="external text external">Archived</a> from the original on 3 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">2 December</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-64"> <span id="mw-reference-text-cite_note-64" class="mw-reference-text"><a href="javascript:if(confirm('https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B08a199fb-ea5a-4aac-b6ef-36bb547ef9e6%7D/fda-approves-ogivri-first-biosimilar-for-certain-breast-stomach-cancers?m_bt=2863263984850  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B08a199fb-ea5a-4aac-b6ef-36bb547ef9e6%7D/fda-approves-ogivri-first-biosimilar-for-certain-breast-stomach-cancers?m_bt=2863263984850'" tppabs="https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B08a199fb-ea5a-4aac-b6ef-36bb547ef9e6%7D/fda-approves-ogivri-first-biosimilar-for-certain-breast-stomach-cancers?m_bt=2863263984850" class="external text external">FDA approves Ogivri, first biosimilar for certain breast, stomach cancers. December 2017</a></span></li><li id="cite_note-65"> <span id="mw-reference-text-cite_note-65" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri" class="external text external">"Ogivri EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 July</span> 2020</span>.</cite></span></li><li id="cite_note-66"> <span id="mw-reference-text-cite_note-66" class="mw-reference-text"><a href="javascript:if(confirm('http://www.samsungbioepis.com/en/newsroom/detail/Samsung-Bioepis-Receives-Regulatory-Approval.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.samsungbioepis.com/en/newsroom/detail/Samsung-Bioepis-Receives-Regulatory-Approval.html'" tppabs="http://www.samsungbioepis.com/en/newsroom/detail/Samsung-Bioepis-Receives-Regulatory-Approval.html" class="external text external">Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar. Nov 2017</a></span></li><li id="cite_note-67"> <span id="mw-reference-text-cite_note-67" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/herzuma  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/herzuma'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/herzuma" class="external text external">"Herzuma EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 July</span> 2020</span>.</cite></span></li><li id="cite_note-FDA-Herzuma-68"> <span id="mw-reference-text-cite_note-FDA-Herzuma-68" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761091s000lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761091s000lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761091s000lbl.pdf" class="external text external">"Herzuma"</a> <span class="cs1-format">(PDF)</span>. <i>U.S. Food and Drug Administration (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">21 December</span> 2018</span>.</cite></span></li><li id="cite_note-69"> <span id="mw-reference-text-cite_note-69" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/kanjinti  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/kanjinti'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/kanjinti" class="external text external">"Kanjinti EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 July</span> 2020</span>.</cite></span></li><li id="cite_note-70"> <span id="mw-reference-text-cite_note-70" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/trazimera  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/trazimera'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/trazimera" class="external text external">"Trazimera EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 July</span> 2020</span>.</cite></span></li><li id="cite_note-71"> <span id="mw-reference-text-cite_note-71" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/zercepac  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/zercepac'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/zercepac" class="external text external">"Zercepac EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">28 July</span> 2020</span>.</cite></span></li><li id="cite_note-72"> <span id="mw-reference-text-cite_note-72" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available'" tppabs="https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available" class="external text external">"FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies"</a>. <i>U.S.Food and Drug Administration (FDA)</i> (Press release). 20 December 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191220192916/https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191220192916/https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available'" tppabs="https://web.archive.org/web/20191220192916/https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available" class="external text external">Archived</a> from the original on 20 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2019</span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<ul><li>Bazell, Robert. <i>Her-2: the making of Herceptin, a revolutionary treatment for breast cancer</i>. Random House, 1998. 214 pages. ISBN<span>&nbsp;</span>0-679-45702-X.</li>
<li><cite id="CITEREFBoseley2006" class="citation news cs1">Boseley, Sarah (29 March 2006). <a href="javascript:if(confirm('http://www.theguardian.com/science/2006/mar/29/medicineandhealth.health  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.theguardian.com/science/2006/mar/29/medicineandhealth.health'" tppabs="http://www.theguardian.com/science/2006/mar/29/medicineandhealth.health" class="external text external">"The selling of a wonder drug"</a>. <i>The Guardian</i>.</cite></li>
<li><cite id="CITEREFDentVermaLatreilleRayson2009" class="citation journal cs1">Dent S, Verma S, Latreille J, Rayson D, Clemons M, Mackey J, Verma S, Lemieux J, Provencher L, Chia S, Wang B, Pritchard K (2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722050  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722050'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722050" class="external text external">"The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer"</a>. <i>Curr Oncol</i>. <b>16</b> (4): 25–35. doi:<a href="javascript:if(confirm('https://doi.org/10.3747%2Fco.v16i4.469  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3747%2Fco.v16i4.469'" tppabs="https://doi.org/10.3747%2Fco.v16i4.469" class="external text external">10.3747/co.v16i4.469</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722050  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722050'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722050" class="external text external">2722050</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19672422  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19672422'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19672422" class="external text external">19672422</a>.</cite></li>
<li><cite id="CITEREFDean2015" class="citation book cs1">Dean L (2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/books/NBK310376/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/books/NBK310376/'" tppabs="https://www.ncbi.nlm.nih.gov/books/NBK310376/" class="external text external">"Trastuzumab (Herceptin) Therapy and ERBB2 (HER2) Genotype"</a>.  In Pratt VM, McLeod HL, Rubinstein WS,  et al. (eds.). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/books/NBK61999/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/books/NBK61999/'" tppabs="https://www.ncbi.nlm.nih.gov/books/NBK61999/" class="external text external"><i>Medical Genetics Summaries</i></a>. National Center for Biotechnology Information (NCBI). PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28520362  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28520362'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28520362" class="external text external">28520362</a>. Bookshelf ID: NBK310376.</cite></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<table role="presentation" class="mbox-small  sistersitebox" style="background-color:#f9f9f9;border:1px solid #aaa;color:#000">
<tbody><tr>
<td class="mbox-image"><figure-inline class="noviewer"><span><img src="../I/m/Wiktionary-logo-en-v2.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Wiktionary-logo-en-v2.svg.png" data-file-width="512" data-file-height="512" data-file-type="drawing" height="40" width="40"></span></figure-inline></td>
<td class="mbox-text plainlist">Look up <i><b><a href="javascript:if(confirm('https://en.wiktionary.org/wiki/Special:Search/trastuzumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wiktionary.org/wiki/Special:Search/trastuzumab'" tppabs="https://en.wiktionary.org/wiki/Special:Search/trastuzumab" title="wiktionary:Special:Search/trastuzumab" class="external">trastuzumab</a></b></i> in Wiktionary, the free dictionary.</td></tr>
</tbody></table>
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/trastuzumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/trastuzumab'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/trastuzumab" class="external text external">"Trastuzumab"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab'" tppabs="https://www.cancer.gov/about-cancer/treatment/drugs/trastuzumab" class="external text external">"Trastuzumab"</a>. <i>National Cancer Institute</i>.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_tumors" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Monoclonal_antibodies_for_tumors" style="font-size:114%;margin:0 4em">Monoclonal antibodies for tumors</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;">Tumor<br></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Human</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Adecatumumab<sup>§</sup></li>
<li>Ascrinvacumab<sup>§</sup></li>
<li>Atezolizumab</li>
<li>Cixutumumab<sup>§</sup></li>
<li>Conatumumab<sup>§</sup></li>
<li>Daratumumab</li>
<li>Drozitumab<sup>§</sup></li>
<li>Duligotumab<sup>§</sup></li>
<li>Dusigitumab<sup>§</sup></li>
<li>Enfortumab vedotin<sup>†</sup></li>
<li>Enoticumab<sup>§</sup></li>
<li>Figitumumab<sup>§</sup></li>
<li>Ganitumab<sup>†</sup></li>
<li>Glembatumumab vedotin<sup>†</sup></li>
<li>Intetumumab<sup>§</sup></li>
<li>Ipilimumab</li>
<li>Iratumumab<sup>§</sup></li>
<li>Istiratumab</li>
<li>Icrucumab<sup>§</sup></li>
<li>Lexatumumab<sup>§</sup></li>
<li>Lucatumumab<sup>§</sup></li>
<li>Mapatumumab<sup>§</sup></li>
<li>Narnatumab<sup>§</sup></li>
<li>Necitumumab</li>
<li>Nesvacumab<sup>§</sup></li>
<li>Nivolumab<sup>#</sup></li>
<li>Ofatumumab</li>
<li>Olaratumab<sup>†</sup></li>
<li>Panitumumab</li>
<li>Patritumab<sup>§</sup></li>
<li>Pembrolizumab<sup>#</sup></li>
<li>Pritumumab<sup>§</sup></li>
<li>Radretumab<sup>§</sup></li>
<li>Ramucirumab</li>
<li>Rilotumumab<sup>†</sup></li>
<li>Robatumumab<sup>§</sup></li>
<li>Seribantumab<sup>§</sup></li>
<li>Tarextumab<sup>§</sup></li>
<li>Teprotumumab<sup>†</sup></li>
<li>Tovetumab<sup>§</sup></li>
<li>Vantictumab<sup>§</sup></li>
<li>Votumumab<sup>§</sup></li>
<li>Zalutumumab<sup>†</sup></li></ul>

<dl><dt><span class="nobold">"-melu-" (melanoma)</span></dt>
<dd>Flanvotumab<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Mouse</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Altumomab pentetate</li>
<li>Anatumomab mafenatox</li>
<li><a href="Technetium_(99mTc)_arcitumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Technetium_(99mTc)_arcitumomab" title="Technetium (99mTc) arcitumomab">Arcitumomab</a></li>
<li>Bectumomab</li>
<li>Blinatumomab</li>
<li>Detumomab</li>
<li><a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab tiuxetan</a></li>
<li>Lilotomab</li>
<li>Minretumomab</li>
<li>Mitumomab</li>
<li>Moxetumomab pasudotox</li>
<li>Naptumomab estafenatox</li>
<li>Nofetumomab merpentan</li>
<li>Pemtumomab<sup>†</sup></li>
<li>Pintumomab</li>
<li>Racotumomab</li>
<li><a href="Indium_(111In)_satumomab_pendetide.htm" tppabs="https://ptable.com/wiki/compounds/A/Indium_(111In)_satumomab_pendetide" title="Indium (111In) satumomab pendetide">Satumomab pendetide</a></li>
<li>Solitomab</li>
<li>Taplitumomab paptox</li>
<li>Tenatumomab</li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a></li>
<li>3F8</li></ul>

<dl><dt><span class="nobold">"-govo-" (ovarian tumor)</span></dt>
<dd>Abagovomab</dd>
<dd>Igovomab</dd>
<dd>Oregovomab</dd></dl>

<dl><dt><span class="nobold">"-pro-" (prostate tumor)</span></dt>
<dd>Capromab pendetide</dd></dl>

<dl><dt><span class="nobold">"-colo-" (colonic tumor)</span></dt>
<dd>Edrecolomab</dd>
<dd>Nacolomab tafenatox</dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Amatuximab<sup>§</sup></li>
<li>Bavituximab<sup>§</sup></li>
<li>Brentuximab vedotin</li>
<li>Carotuximab<sup>†</sup></li>
<li><a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Derlotuximab biotin<sup>§</sup></li>
<li>Dinutuximab</li>
<li>Ensituximab<sup>§</sup></li>
<li>Futuximab<sup>§</sup></li>
<li>Girentuximab<sup>†</sup></li>
<li>Indatuximab ravtansine<sup>§</sup></li>
<li>Isatuximab</li>
<li>Loncastuximab tesirine</li>
<li>Margetuximab<sup>†</sup></li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a><sup>#</sup></li>
<li>Siltuximab</li>
<li>Ublituximab<sup>†</sup></li>
<li>IMAB362</li></ul>

<p>"-mexi-" (melanoma): Ecromeximab<sup>§</sup></p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Humanized</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abituzumab<sup>§</sup></li>
<li><a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a></li>
<li>Belantamab mafodotin</li>
<li>Bevacizumab</li>
<li>Bivatuzumab mertansine<sup>§</sup></li>
<li>Brontictuzumab<sup>§</sup></li>
<li>Cantuzumab mertansine<sup>§</sup></li>
<li>Cantuzumab ravtansine<sup>§</sup></li>
<li>Cirmtuzumab</li>
<li>Citatuzumab bogatox<sup>§</sup></li>
<li>Clivatuzumab tetraxetan</li>
<li>Cofetuzumab pelidotin</li>
<li>Dacetuzumab<sup>§</sup></li>
<li>Demcizumab<sup>§</sup></li>
<li>Dalotuzumab<sup>§</sup></li>
<li>Denintuzumab mafodotin<sup>§</sup></li>
<li>Elotuzumab</li>
<li>Emactuzumab<sup>§</sup></li>
<li>Emibetuzumab<sup>§</sup></li>
<li>Enoblituzumab<sup>§</sup></li>
<li>Etaracizumab<sup>§</sup></li>
<li>Farletuzumab<sup>§</sup></li>
<li>Ficlatuzumab<sup>§</sup></li>
<li>Flotetuzumab<sup>§</sup></li>
<li>Gemtuzumab ozogamicin</li>
<li>Imgatuzumab<sup>§</sup></li>
<li>Inotuzumab ozogamicin<sup>†</sup></li>
<li>Labetuzumab<sup>§</sup></li>
<li>Lifastuzumab vedotin<sup>§</sup></li>
<li>Lintuzumab<sup>§</sup></li>
<li>Lorvotuzumab mertansine<sup>§</sup></li>
<li>Lumretuzumab<sup>§</sup></li>
<li>Matuzumab<sup>§</sup></li>
<li>Milatuzumab<sup>§</sup></li>
<li>Nimotuzumab<sup>†</sup></li>
<li>Obinutuzumab</li>
<li>Ocaratuzumab<sup>§</sup></li>
<li>Otlertuzumab<sup>§</sup></li>
<li>Onartuzumab<sup>§</sup></li>
<li>Oportuzumab monatox<sup>†</sup></li>
<li>Parsatuzumab<sup>§</sup></li>
<li>Pertuzumab</li>
<li>Pinatuzumab vedotin<sup>§</sup></li>
<li>Polatuzumab vedotin<sup>†</sup></li>
<li>Rosmantuzumab</li>
<li>Rovalpituzumab tesirine<sup>†</sup></li>
<li>Sacituzumab govitecan</li>
<li>Sibrotuzumab<sup>§</sup></li>
<li>Simtuzumab<sup>§</sup></li>
<li>Tacatuzumab tetraxetan<sup>§</sup></li>
<li>Tigatuzumab<sup>§</sup></li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a><sup>#</sup></li>
<li>Tucotuzumab celmoleukin<sup>§</sup></li>
<li>Vandortuzumab vedotin<sup>§</sup></li>
<li>Vanucizumab<sup>§</sup></li>
<li>Veltuzumab<sup>§</sup></li>
<li>Vorsetuzumab mafodotin<sup>§</sup></li>
<li>CBR96-doxorubicin immunoconjugate</li>
<li>PankoMab</li></ul>

<dl><dt><span class="nobold">"-gozu-" (ovarian tumor)</span></dt>
<dd>Sofituzumab vedotin<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Rat/mouse hybrid<br></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Catumaxomab</li>
<li>Ertumaxomab<sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric + humanized<br></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Depatuxizumab mafodotin<sup>†</sup></li>
<li>Duvortuxizumab</li>
<li>Ontuxizumab<sup>§</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Growth_factor_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Growth_factor_receptor_modulators" style="font-size:114%;margin:0 4em">Growth factor receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Angiopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Angiopoietin 1</li>
<li>Angiopoietin 4</li></ul>

<ul><li><i>Antagonists:</i> Angiopoietin 2</li>
<li><span class="new">Angiopoietin 3</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">CE-245677</span></li>
<li>Rebastinib</li></ul>

<ul><li><i>Antibodies:</i> Evinacumab (against angiopoietin 3)</li>
<li>Nesvacumab (against angiopoietin 2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CNTF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Axokine</li>
<li>CNTF</li>
<li><span class="new">Dapiclermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF (ErbB)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF<br><small>(ErbB1/HER1)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Amphiregulin</li>
<li>Betacellulin</li>
<li>EGF (urogastrone)</li>
<li>Epigen</li>
<li>Epiregulin</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Murodermin</li>
<li>Nepidermin</li>
<li>Transforming growth factor alpha (TGFα)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><span class="new">Agerafenib</span></li>
<li>Brigatinib</li>
<li>Canertinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Grandinin</li>
<li>Icotinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li>
<li>Osimertinib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> <a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><span class="new">Depatuxizumab</span></li>
<li>Depatuxizumab mafodotin</li>
<li>Futuximab</li>
<li>Imgatuzumab</li>
<li>Matuzumab</li>
<li>Necitumumab</li>
<li>Nimotuzumab</li>
<li>Panitumumab</li>
<li>Zalutumumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB2/HER2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: <i>Unknown/none</i></li></ul>

<ul><li><i>Antibodies:</i> Ertumaxomab</li>
<li>Pertuzumab</li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a></li>
<li><span class="new">Trastuzumab duocarmazine</span></li>
<li>Trastuzumab emtansine</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Mubritinib</li>
<li>Neratinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB3/HER3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))</li></ul>

<ul><li><i>Antibodies:</i> Duligotumab</li>
<li>Patritumab</li>
<li>Seribantumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB4/HER4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Betacellulin</li>
<li>Epigen</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Neuregulins (heregulins) (1, 2, 3, 4, <span class="new">5 (tomoregulin, TMEFF)</span>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)</li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Trafermin</li>
<li><span class="new">Velafermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)</li>
<li><a href="Palifermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Palifermin" title="Palifermin">Palifermin</a></li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Aprutumab</span></li>
<li><span class="new">Aprutumab ixadotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)</li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> Burosumab (against FGF23)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)</li>
<li>Trafermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> FGF15/19</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">HGF (c-Met)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Hepatocyte growth factor</li></ul>

<ul><li><i>Potentiators:</i> Dihexa (PNB-0408)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AM7</span></li>
<li><span class="new">AMG-458</span></li>
<li><span class="new">Amuvatinib</span></li>
<li><span class="new">BMS-777607</span></li>
<li>Cabozantinib</li>
<li>Crizotinib</li>
<li>Foretinib</li>
<li><span class="new">Golvatinib</span></li>
<li><span class="new">INCB28060</span></li>
<li><span class="new">JNJ-38877605</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li><span class="new">MK-2461</span></li>
<li><span class="new">PF-04217903</span></li>
<li><span class="new">PF-2341066</span></li>
<li><span class="new">PHA-665752</span></li>
<li><span class="new">SU-11274</span></li>
<li>Tivantinib</li>
<li>Volitinib</li></ul>

<ul><li><i>Antibodies:</i> Emibetuzumab</li>
<li>Ficlatuzumab</li>
<li>Flanvotumab</li>
<li>Onartuzumab</li>
<li>Rilotumumab</li>
<li><span class="new">Telisotuzumab</span></li>
<li><span class="new">Telisotuzumab vedotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: des(1-3)IGF-1</li>
<li>Insulin-like growth factor-1 (somatomedin C)</li>
<li>IGF-1 LR3</li>
<li>Insulin-like growth factor-2 (somatomedin A)</li>
<li><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulin</a></li>
<li><a href="Mecasermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mecasermin" title="Mecasermin">Mecasermin</a></li>
<li>Mecasermin rinfabate</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">BMS-754807</span></li>
<li>Linsitinib</li>
<li><span class="new">NVP-ADW742</span></li>
<li><span class="new">NVP-AEW541</span></li>
<li><span class="new">OSl-906</span></li></ul>

<ul><li><i>Antibodies:</i> <span class="new">AVE-1642</span></li>
<li>Cixutumumab</li>
<li>Dalotuzumab</li>
<li>Figitumumab</li>
<li>Ganitumab</li>
<li>Robatumumab</li>
<li><span class="new">R1507</span></li>
<li>Teprotumumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Insulin-like growth factor-2 (somatomedin A)</li></ul>

<ul><li><i>Antibodies:</i> Dusigitumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Binding proteins:</i> IGFBP (1, 2, 3, 4, 5, 6, 7)</li></ul>

<ul><li><i>Cleavage products/derivatives with unknown target:</i> <span class="new">Glypromate (GPE, (1-3)IGF-1)</span></li>
<li>Trofinetide</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">LNGF (p75<sup>NTR</sup>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BDNF</li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li>NGF</li>
<li>NT-3</li>
<li>NT-4</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><span class="new">EVT-901 (SAR-127963)</span></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Antibodies:</i> <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">LEVI-04 (p75<sup>NTR</sup>-Fc)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PDGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Becaplermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Becaplermin" title="Becaplermin">Becaplermin</a></li>
<li>Platelet-derived growth factor (A, B, C, D)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li>Crenolanib</li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Lenvatinib</li>
<li>Masitinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Radotinib</li>
<li>Quizartinib</li>
<li>Ripretinib</li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li>Toceranib</li></ul>

<ul><li><i>Antibodies:</i> Olaratumab</li>
<li>Ramucirumab</li>
<li>Tovetumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">RET (GFL)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Glial cell line-derived neurotrophic factor (GDNF)</li>
<li><span class="new">Liatermin</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neurturin (NRTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Artemin (ARTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα4</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Persephin (PSPN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Ancestim</li>
<li>Stem cell factor</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Masitinib</li>
<li>Nilotinib</li>
<li>Pazopanib</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Trk</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkA</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li><span class="new">Gambogic amide</span></li>
<li>NGF</li>
<li>Tavilermide</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li>FX007</li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Negative allosteric modulators:</i> <span class="new">VM-902A</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">Milciclib</span></li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li>
<li>Rebastinib</li>
<li><span class="new">SNA-120 (pegylated K252a)</span>)</li></ul>

<ul><li><i>Antibodies:</i> <i>Against TrkA:</i> <span class="new">GBR-900</span>; <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">ReN-1820 (TrkAd5)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkB</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">3,7-DHF</span></li>
<li><span class="new">3,7,8,2'-THF</span></li>
<li>4'-DMA-7,8-DHF</li>
<li><span class="new">7,3'-DHF</span></li>
<li>7,8-DHF</li>
<li><span class="new">7,8,2'-THF</span></li>
<li>7,8,3'-THF</li>
<li><a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BDNF</li>
<li>BNN-20</li>
<li>Deoxygedunin</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Deprenyl" title="Deprenyl" class="mw-redirect">Deprenyl</a></li>
<li>Diosmetin</li>
<li><span class="new">DMAQ-B1</span></li>
<li>HIOC</li>
<li>LM22A-4</li>
<li><a href="N-Acetylserotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a></li>
<li>NT-3</li>
<li>NT-4</li>
<li>Norwogonin (5,7,8-THF)</li>
<li>R7</li>
<li>R13</li>
<li><span class="new">TDP6</span></li></ul>

<ul><li><i>Antagonists:</i> ANA-12</li>
<li>Cyclotraxin B</li>
<li>Gossypetin (3,5,7,8,3',4'-HHF)</li></ul>

<ul><li><i>Ligands:</i> <a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkC</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BNN-20</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li>NT-3</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VEGF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Placental growth factor (PGF)</li>
<li>Ripretinib</li>
<li><span class="new">Telbermin</span></li>
<li>VEGF (A, B, C, D (FIGF))</li></ul>

<ul><li><i>Allosteric modulators:</i> Cyclotraxin B</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li><span class="new">Altiratinib</span></li>
<li>Axitinib</li>
<li>Cabozantinib</li>
<li>Cediranib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Lenvatinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Pegaptanib</li>
<li>Rebastinib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li>
<li>Tivozanib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> Alacizumab pegol</li>
<li>Bevacizumab</li>
<li>Icrucumab</li>
<li>Ramucirumab</li>
<li><a href="Ranibizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranibizumab" title="Ranibizumab">Ranibizumab</a></li></ul>

<ul><li><i>Decoy receptors:</i> Aflibercept</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional growth factors:</i> Adrenomedullin</li>
<li>Colony-stimulating factors (see here instead)</li>
<li>Connective tissue growth factor (CTGF)</li>
<li>Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)</li>
<li>Erythropoietin (see here instead)</li>
<li>Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)</li>
<li>Glia maturation factor (GMF)</li>
<li>Hepatoma-derived growth factor (HDGF)</li>
<li>Interleukins/T-cell growth factors (see here instead)</li>
<li>Leukemia inhibitory factor (LIF)</li>
<li>Macrophage-stimulating protein (MSP; HLP, HGFLP)</li>
<li>Midkine (NEGF2)</li>
<li>Migration-stimulating factor (MSF; PRG4)</li>
<li>Oncomodulin</li>
<li>Pituitary adenylate cyclase-activating peptide (PACAP)</li>
<li>Pleiotrophin</li>
<li>Renalase</li>
<li>Thrombopoietin (see here instead)</li>
<li>Wnt signaling proteins</li></ul>

<ul><li><i>Additional growth factor receptor modulators:</i> Cerebrolysin (neurotrophin mixture)</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Cytokine receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>









<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-06" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Trastuzumab&oldid=971429821  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Trastuzumab&oldid=971429821'" tppabs="https://en.wikipedia.org/wiki/?title=Trastuzumab&oldid=971429821">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>